Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1992 Dec;90(6):2340–2347. doi: 10.1172/JCI116123

Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.

T L Ortel 1, M A Quinn-Allen 1, L A Charles 1, D Devore-Carter 1, W H Kane 1
PMCID: PMC443388  PMID: 1281831

Abstract

Coagulation Factor V is an essential component of the prothrombinase complex, which activates the zymogen prothrombin to thrombin. A patient was described who developed a Factor V inhibitor that neutralized the procoagulant activity of Factor V and resulted in a fatal hemorrhagic diathesis (Coots, M. C., A. F. Muhleman, and H. I. Glueck. 1978. Am. J. Hematol. 4:193-206). This inhibitor was shown to be an IgG antibody that bound to the light chain of Factor V. Using a series of light chain deletion mutants, we have found that this antibody binds to the second C-type domain of the light chain. Both inhibitor IgG and Fab fragments rapidly neutralized the procoagulant activity of Factor Va, implying that the neutralization resulted from specific binding to the C2 domain. We have previously demonstrated that deletion of the C2 domain results in loss of procoagulant activity, as well as loss of phosphatidylserine-specific binding. Confirming these results, both inhibitor IgG and Fab fragments interfered with phosphatidylserine-specific binding of Factor V. Conversely, preincubation of Factor Va with procoagulant phospholipids protected the cofactor from inactivation by the inhibitor. Our results suggest that this inhibitor neutralizes the procoagulant activity of Factor Va by interfering with the C2-mediated interaction with phospholipid surfaces, thereby disrupting formation of the prothrombinase complex.

Full text

PDF
2340

Images in this article

2343Image
on p.2343
2343Image
on p.2343
2344Image
on p.2344
2344Image
on p.2344

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Annamalai A. E., Rao A. K., Chiu H. C., Wang D., Duttá-Roy A. K., Walsh P. N., Colman R. W. Epitope mapping of functional domains of human factor Va with human and murine monoclonal antibodies. Evidence for the interaction of heavy chain with factor Xa and calcium. Blood. 1987 Jul;70(1):139–146. [PubMed] [Google Scholar]
  2. Arai M., Scandella D., Hoyer L. W. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest. 1989 Jun;83(6):1978–1984. doi: 10.1172/JCI114107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barrowcliffe T. W., Kemball-Cook G., Gray E. Binding to phospholipid protects factor VIII from inactivation by human antibodies. J Lab Clin Med. 1983 Jan;101(1):34–43. [PubMed] [Google Scholar]
  4. Chediak J., Ashenhurst J. B., Garlick I., Desser R. K. Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions. Blood. 1980 Nov;56(5):835–841. [PubMed] [Google Scholar]
  5. Chiu H. C., Rao A. K., Beckett C., Colman R. W. Immune complexes containing factor V in a patient with an acquired neutralizing antibody. Blood. 1985 Apr;65(4):810–818. [PubMed] [Google Scholar]
  6. Coots M. C., Muhleman A. F., Glueck H. I. Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol. 1978;4(2):193–206. doi: 10.1002/ajh.2830040212. [DOI] [PubMed] [Google Scholar]
  7. Fulcher C. A., Lechner K., de Graaf Mahoney S. Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. Blood. 1988 Oct;72(4):1348–1356. [PubMed] [Google Scholar]
  8. Green D., Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981 Jun 30;45(3):200–203. [PubMed] [Google Scholar]
  9. Hurtubise P. E., Coots M. C., Jacob D. J., Muhleman A. F., Glueck H. I. A monoclonal IgG4 (lambda) with factor V inhibitory activity. J Immunol. 1979 May;122(5):2119–2121. [PubMed] [Google Scholar]
  10. Kalafatis M., Jenny R. J., Mann K. G. Identification and characterization of a phospholipid-binding site of bovine factor Va. J Biol Chem. 1990 Dec 15;265(35):21580–21589. [PubMed] [Google Scholar]
  11. Kane W. H., Davie E. W. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood. 1988 Mar;71(3):539–555. [PubMed] [Google Scholar]
  12. Kane W. H., Devore-Carter D., Ortel T. L. Expression and characterization of recombinant human factor V and a mutant lacking a major portion of the connecting region. Biochemistry. 1990 Jul 24;29(29):6762–6768. doi: 10.1021/bi00481a003. [DOI] [PubMed] [Google Scholar]
  13. Krishnaswamy S., Mann K. G. The binding of factor Va to phospholipid vesicles. J Biol Chem. 1988 Apr 25;263(12):5714–5723. [PubMed] [Google Scholar]
  14. Laue T. M., Lu R., Krieg U. C., Esmon C. T., Johnson A. E. Ca2+-dependent structural changes in bovine blood coagulation factor Va and its subunits. Biochemistry. 1989 May 30;28(11):4762–4771. doi: 10.1021/bi00437a037. [DOI] [PubMed] [Google Scholar]
  15. Lian E. C., Larcada A. F., Chiu A. Y. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med. 1989 May 15;110(10):774–778. doi: 10.7326/0003-4819-110-10-774. [DOI] [PubMed] [Google Scholar]
  16. Lottenberg R., Kentro T. B., Kitchens C. S. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med. 1987 Jun;147(6):1077–1081. doi: 10.1001/archinte.147.6.1077. [DOI] [PubMed] [Google Scholar]
  17. Lubahn B. C., Ware J., Stafford D. W., Reisner H. M. Identification of a F.VIII epitope recognized by a human hemophilic inhibitor. Blood. 1989 Feb;73(2):497–499. [PubMed] [Google Scholar]
  18. Mann K. G., Nesheim M. E., Church W. R., Haley P., Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990 Jul 1;76(1):1–16. [PubMed] [Google Scholar]
  19. Miletich J. P., Jackson C. M., Majerus P. W. Properties of the factor Xa binding site on human platelets. J Biol Chem. 1978 Oct 10;253(19):6908–6916. [PubMed] [Google Scholar]
  20. Nesheim M. E., Nichols W. L., Cole T. L., Houston J. G., Schenk R. B., Mann K. G., Bowie E. J. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest. 1986 Feb;77(2):405–415. doi: 10.1172/JCI112318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nesheim M. E., Pittman D. D., Wang J. H., Slonosky D., Giles A. R., Kaufman R. J. The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem. 1988 Nov 5;263(31):16467–16470. [PubMed] [Google Scholar]
  22. Ortel T. L., Devore-Carter D., Quinn-Allen M., Kane W. H. Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain. J Biol Chem. 1992 Feb 25;267(6):4189–4198. [PubMed] [Google Scholar]
  23. Pryzdial E. L., Mann K. G. The association of coagulation factor Xa and factor Va. J Biol Chem. 1991 May 15;266(14):8969–8977. [PubMed] [Google Scholar]
  24. Rapaport S. I., Zivelin A., Minow R. A., Hunter C. S., Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol. 1992 Jan;97(1):84–91. doi: 10.1093/ajcp/97.1.84. [DOI] [PubMed] [Google Scholar]
  25. Scandella D., Mattingly M., de Graaf S., Fulcher C. A. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood. 1989 Oct;74(5):1618–1626. [PubMed] [Google Scholar]
  26. Wilson D. B., Salem H. H., Mruk J. S., Maruyama I., Majerus P. W. Biosynthesis of coagulation Factor V by a human hepatocellular carcinoma cell line. J Clin Invest. 1984 Mar;73(3):654–658. doi: 10.1172/JCI111256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Zehnder J. L., Leung L. L. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood. 1990 Nov 15;76(10):2011–2016. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES